Among the drugs in clinical development, custirsen, cabozantinib and dasatinib are among the most promising.
(PRWEB UK) 27 May 2014
In the peer-reviewed journal European Oncology & Haematology, Amit Bahl discusses the expansion in the number of therapeutic options for CRPC and the regulatory approval of several agents.
Castration-resistant prostate cancer has a poor prognosis: current chemotherapeutic approaches ultimately result in resistance and are associated with survival rates of less than 2 years. However, the last decade has seen an expansion in the number of therapeutic options for CRPC and the regulatory approval of several agents, including the chemotherapy drug cabazitaxel and the targeted agents abiraterone acetate, enzalatumide and denosumab. Novel targeted agents inhibit androgen receptor-mediated signalling, and non-hormonal targets, including apoptosis, signal transduction pathway inhibitors, angiogenesis and bone and immune microenvironments. Clinical trials of these agents, however, have demonstrated varied efficacy. Among the drugs in clinical development, custirsen, cabozantinib and dasatinib are among the most promising. There is a requirement for studies directly comparing agents, and for improved patient selection to identify patients benefitting from a particular therapy.
To continue reading this peer-reviewed article for free please visit:http://www.touchoncology.com/articles/castration-resistant-prostate-cancer-chemotherapies-and-molecular-targets